These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36028470)

  • 21. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.
    Cui L; Chen R; Subedi S; Yu Q; Gong Y; Chen Z; Shi Y
    Int Immunopharmacol; 2018 Sep; 62():46-58. PubMed ID: 29990694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bayesian network meta-analysis of head-to-head trials for complete resolution of nail psoriasis.
    Husein-ElAhmed H; Husein-ElAhmed S
    Clin Exp Dermatol; 2023 Jul; 48(8):895-902. PubMed ID: 37052062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
    Reich K; Burden AD; Eaton JN; Hawkins NS
    Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A network meta-analysis for the comparison of efficacy and safety of interleukin (IL)-23 targeted drugs in the treatment of moderate to severe psoriasis.
    Shi J; Xu J; Chen Y
    Dermatol Ther; 2020 Jul; 33(4):e13802. PubMed ID: 32521069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
    Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
    Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis.
    Leonardi CL; See K; Burge R; Sun Z; Zhang Y; Mallbris L; Garrelts A; Warren RB
    Adv Ther; 2022 May; 39(5):2256-2269. PubMed ID: 35316500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis.
    Pan R; Wang X; Shu M; Das J; Kalra M; Wang Z
    Chin Med J (Engl); 2022 Jan; 135(1):11-19. PubMed ID: 34882622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
    Lasa JS; Olivera PA; Danese S; Peyrin-Biroulet L
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):161-170. PubMed ID: 34856198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis.
    Núñez M; Huete T; de la Cueva P; Sacristán JA; Hartz S; Dilla T
    Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):546-553. PubMed ID: 30851873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
    Zidane M; Dressler C; Gaskins M; Nast A
    JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis.
    Blauvelt A; Gooderham M; Griffiths CEM; Armstrong AW; Zhu B; Burge R; Gallo G; Guo J; Garrelts A; Lebwohl M
    Dermatol Ther (Heidelb); 2022 Mar; 12(3):727-740. PubMed ID: 35195887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
    Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
    Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.
    Mahil SK; Ezejimofor MC; Exton LS; Manounah L; Burden AD; Coates LC; de Brito M; McGuire A; Murphy R; Owen CM; Parslew R; Woolf RT; Yiu ZZN; Uthman OA; Mohd Mustapa MF; Smith CH
    Br J Dermatol; 2020 Oct; 183(4):638-649. PubMed ID: 32562551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologics for pediatric psoriasis: A systematic review and meta-analysis.
    Sun HY; Phan K; Paller AS; Sebaratnam DF
    Pediatr Dermatol; 2022 Jan; 39(1):42-48. PubMed ID: 34888919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antistreptococcal interventions for guttate and chronic plaque psoriasis.
    Dupire G; Droitcourt C; Hughes C; Le Cleach L
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD011571. PubMed ID: 30835819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Onset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis.
    Papp KA; Lebwohl MG
    J Drugs Dermatol; 2018 Mar; 17(3):247-250. PubMed ID: 29537442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis.
    Fahrbach K; Sarri G; Phillippo DM; Neupane B; Martel SE; Kiri S; Reich K
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):1965-1998. PubMed ID: 34549383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.